Ownership Summary
Quarter ending 30 Jun, 2026
Inhibrx Biosciences, Inc. (NASDAQ:INBX) has 164 institutional investors with active 13F positions as of June 2026.
- Collectively, these holders controlled 84.2% of Inhibrx Biosciences's outstanding shares in June 2026, up from 74.6% in March 2026.
- They increased total shares held in Inhibrx Biosciences by 17.98% from the prior quarter, while the number of investors in INBX increased 88.51% year over year.
- Of these 164 holders, 110 added to their stakes in Inhibrx Biosciences, 39 trimmed positions, and 15 made no changes.
- The aggregate institutional position in Inhibrx Biosciences amounted to 13.2Mn shares as of June 2026, up by 2.01Mn shares quarter on quarter, and up 3.82Mn shares year over year.
- As of June 30, 2026, Morgan Stanley held the largest stake in Inhibrx Biosciences with 1.31Mn shares, accounting for 8.35% of total shares outstanding.
- Leading buyers of Inhibrx Biosciences shares for the quarter ending June 2026 were Bank Of America Corp /De/ (808.46K), Schonfeld Strategic Advisors LLC (442.76K), Parkman Healthcare Partners LLC (256.95K), Goldman Sachs Group Inc (243.1K), First Turn Management, LLC (164.78K).
- Top sellers of INBX stock for the quarter ending June 2026 included VIKING GLOBAL INVESTORS LP (313.78K), MILLENNIUM MANAGEMENT LLC (180.66K), PERCEPTIVE ADVISORS LLC (144.94K), SummitTX Capital, L.P. (122.57K), Sofinnova Investments, Inc. (102.93K).
- Business Quant data shows the 10 biggest positions in Inhibrx Biosciences as of June 2026 are held by Morgan Stanley (1.31Mn), PERCEPTIVE ADVISORS LLC (1.3Mn), VIKING GLOBAL INVESTORS LP (1.12Mn), HighTower Advisors, LLC (870.55K), Bank Of America Corp /De/ (841.14K), BlackRock, Inc. (825.97K), Schonfeld Strategic Advisors LLC (697.59K), State Street Corp (640.46K), VANGUARD CAPITAL MANAGEMENT LLC (492.48K), Woodline Partners LP (400.89K).